Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:activeIngredient |
selinexor
|
| gptkbp:administeredBy |
gptkb:carfilzomib
gptkb:dexamethasone gptkb:bortezomib gptkb:pomalidomide |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:China
gptkb:United_States |
| gptkbp:ATCCode |
L01XX60
|
| gptkbp:brand |
Xpovio
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Karyopharm_Therapeutics
Antengene Corporation |
| https://www.w3.org/2000/01/rdf-schema#label |
ATG-010 (selinexor)
|
| gptkbp:indication |
multiple myeloma
diffuse large B-cell lymphoma |
| gptkbp:mechanismOfAction |
selective inhibitor of nuclear export
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
anorexia fatigue hyponatremia thrombocytopenia |
| gptkbp:target |
exportin 1 (XPO1)
|
| gptkbp:bfsParent |
gptkb:Antengene
|
| gptkbp:bfsLayer |
7
|